Chart's improving (down one cent to .12 - 7.5%) March 29th
https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=ca%3Aili&x=45&y=10&time=100&startdate=2%2F4%2F2015&enddate=4%2F21%2F2022&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&style=320&size=3&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=9

Did the same upgap as rockteck (its' neighbour)

https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=&symb=ca%3Arck&x=55&y=15&time=100&startdate=2%2F4%2F2015&enddate=4%2F21%2F2022&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&style=320&size=3&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=9

UPDATE 1-Interleukin gets FDA inquiry on genetic tests

http://www.reuters.com/article/idCNSGE66K0L820100721?rpc=44

Interleukin Genetics to Present at Upcoming Biotech Industry Meetings

Press Release Source: Interleukin Genetics, Inc. On Monday May 3, 2010, 7:30 am EDT
WALTHAM, Mass., May 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that CEO Lewis H. Bender will moderate and co-present a panel discussion titled "Effective Use of Biomarkers in Early to Late-Stage Drug Development: How to Improve Efficacy and Commercial Success" at the BIO International Convention, being held May 3-6, 2010 in Chicago, IL. The panel discussion will be held Wednesday, May 5, from 8-9:30 a.m. CDT in Room N426B at McCormick Place. Co-presenting at BIO alongside Interleukin Genetics will be PGxHealth LLC, a Clinical Data company, Merck Research Laboratories and Nordic Biosciences.

In addition, Interleukin Genetics will present at the Rodman & Renshaw 6th Annual Global Healthcare Conference, to be held May 16-18, 2010 at the Grosvenor House Hotel, London, UK. Mr. Bender will present on behalf of the company at 3:15 p.m. GMT in the Aldford Suite on Monday, May 17. A live audio and webcast of the corporate presentation will be available. The presentation will be archived for 90 days and available on the Investor Relations section of the Interleukin Genetics website.

i wish i got in at that price...i bought at .97...disappointed that it hasnt done anything. public replies only, cant private reply....thx

anyone here??? geeze, should i just dump this dog with fleas?

http://www.nasdaq.com/asp/quotes_sec.asp?symbol=ili&selected=ili

http://www.mffais.com/ili

http://www.form4oracle.com/company/interleukin-genetics-inc-ili?id=1112

ILI coming on CNBC in 10 min

Surprised it didn't have more of a run today...

New gene test may help you pick your diet: report
Reuters

Vegetables at a California supermarket Reuters – Vegetables are seen at a LaJolla, California supermarket in this May 13, 2008 file photo. REUTERS/Mike …

* Look Thinner Without Having To Count Calories Play Video Weight Loss Video:Look Thinner Without Having To Count Calories WBZ Boston
* Conscious Eating Play Video Weight Loss Video:Conscious Eating ABC News
* Does the Shake Weight work? Play Video Weight Loss Video:Does the Shake Weight work? WCNC Charlotte

By Maggie Fox, Health and Science Editor Maggie Fox, Health And Science Editor – Wed Mar 3, 5:00 pm ET

WASHINGTON (Reuters) – Can't lose weight on a low-fat diet? Maybe you need to cut carbs instead, and a new genetic test may point the way, maker Interleukin Genetics Inc reported on Wednesday.

The small study of about 140 overweight or obese women showed that those on diets "appropriate" for their genetic makeup lost more weight than those on less appropriate diets, researchers told an American Heart Association meeting.

"The potential of using genetic information to achieve this magnitude of weight loss without pharmaceutical intervention would be important in helping to solve the pervasive problem of excessive weight in our society," Christopher Gardner at Stanford University in California, who worked on the study, said in a statement.

Massachusetts-based Interleukin's $149 test looks for mutations in three genes, known as FABP2, PPARG and ADRB2.

The company says 39 percent of white Americans have the low-fat genotype, 45 percent have the type that responds best to a diet low in processed carbohydrates and an unlucky 16 percent have gene mutations that mean they have to watch both fat and processed carbohydrates.

The researchers randomly assigned around 140 women to one of four diets -- the low-carb Atkins diet, the ultra low-fat Ornish diet, the very low-fat LEARN diet or the more balanced Zone diet.

Interleukin went back and tested about 100 of the women for their DNA by using a cheek swab and then looked to see if the women on the "right" diets lost more weight.

MOST EFFECTIVE MATCHES

Over a year, people on diets appropriate to their genetic makeup, as determined by the test, lost 5.3 percent of body weight. People on mismatched diets lost 2.3 percent, the Stanford researchers told the meeting.

Cholesterol levels improved in line with weight loss, they said.

The company said the test looks for genes that affect metabolism.

"One of the gene variations affects absorption of fats from the intestine," Ken Kornman, chief scientific officer at Interleukin, said in a telephone interview. He said people with that particular mutation absorb more fat from their food and thus should avoid fat if they want to lose weight.

Another of the variations affects insulin response -- the body's production of insulin to metabolize sugar, he said. Simple carbohydrates such as sugar and processed flour stimulate people with that particular gene type to store more of the energy as fat.

Ten percent to 16 percent of people have both mutations, and must watch both carbs and fat, Kornman said.

"What we don't know is if they are on the right diet for their genotype whether it affects satiety or feeling full," he said. He said the company planned broader studies to ask these questions.

Interleukin markets the test under the brand name Inherent Health. It also can test who might best lose weight in response to exercise.

(Editing by Xavier Briand and Todd Eastham)

UPDATE 1-New gene test may help you pick your diet-report
Wed Mar 3, 2010 4:56pm ESTStocks
Interleukin Genetics, Inc.

* Gene type predicted best response to certain diets

* Approach could help obese lose weight without drugs

(Updates throughout with quotes from company)

By Maggie Fox, Health and Science Editor

WASHINGTON, March 3 (Reuters) - Can't lose weight on a low-fat diet? Maybe you need to cut carbs instead, and a new genetic test may point the way, maker Interleukin Genetics Inc (ILI.A) reported on Wednesday.

The small study of about 140 overweight or obese women showed that those on diets "appropriate" for their genetic makeup lost more weight than those on less appropriate diets, researchers told an American Heart Association meeting.

"The potential of using genetic information to achieve this magnitude of weight loss without pharmaceutical intervention would be important in helping to solve the pervasive problem of excessive weight in our society," Christopher Gardner at Stanford University in California, who worked on the study, said in a statement.

Massachusetts-based Interleukin's $149 test looks for mutations in three genes, known as FABP2, PPARG and ADRB2.

The company says 39 percent of white Americans have the low-fat genotype, 45 percent have the type that responds best to a diet low in processed carbohydrates and an unlucky 16 percent have gene mutations that mean they have to watch both fat and processed carbohydrates.

The researchers randomly assigned around 140 women to one of four diets -- the low-carb Atkins diet, the ultra low-fat Ornish diet, the very low-fat LEARN diet or the more balanced Zone diet.

Interleukin went back and tested about 100 of the women for their DNA by using a cheek swab and then looked to see if the women on the "right" diets lost more weight.

MOST EFFECTIVE MATCHES

Over a year, people on diets appropriate to their genetic makeup, as determined by the test, lost 5.3 percent of body weight. People on mismatched diets lost 2.3 percent, the Stanford researchers told the meeting.

Cholesterol levels improved in line with weight loss, they said.

The company said the test looks for genes that affect metabolism.

"One of the gene variations affects absorption of fats from the intestine," Ken Kornman, chief scientific officer at Interleukin, said in a telephone interview. He said people with that particular mutation absorb more fat from their food and thus should avoid fat if they want to lose weight.

Another of the variations affects insulin response -- the body's production of insulin to metabolize sugar, he said. Simple carbohydrates such as sugar and processed flour stimulate people with that particular gene type to store more of the energy as fat.

Ten percent to 16 percent of people have both mutations, and must watch both carbs and fat, Kornman said.

"What we don't know is if they are on the right diet for their genotype whether it affects satiety or feeling full," he said. He said the company planned broader studies to ask these questions.

Interleukin markets the test under the brand name Inherent Health. It also can test who might best lose weight in response to exercise. (Editing by Xavier Briand and Todd Eastham)

ILI bot the dip earlier ...

hi surf long time no see

ILI breaking above the short term chart pattern:

http://www.mffais.com/ili

http://www.nasdaq.com/asp/quotes_sec.asp?symbol=ili&selected=ili

Interleukin, cash strapped, eyes $75M offeringBoston Business Journal - by Craig M. Douglas

Interleukin Genetics Inc., a developer of genetics-based tests for the consumer market, has filed paperwork to sell up to $75 million in stock and debt.

The company did not break out specifics of the securities to be registered for sale, only noting that “we may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants, rights or purchase contracts to purchase any of such securities” up to the dollar value indicated.

The company made the filing with the Securities and Exchange Commission Wednesday.

Based in Waltham, Mass., Interleukin’s products include swabs and related tools that enable people to collect genetic material as well as tests that monitor everything from nuitritional health to the onset of periodontal disease. The company said it plans to use the offering’s proceeds to support its operations and potentially address other financial obligations.

Interleukin (AMEX: ILI) had $1.4 million in cash and cash equivalents on its books as of Sept. 30, while its operations burned through $3.9 million in cash during the preceding nine months.

ILI newly found "gem " Surf?
tia
GL

Interleukin Genetics Launches Bone Health Genetic Test to Identify Individuals at Higher Risk for Spine Fracture and Low Bone Mineral Density
Test Available Under Inherent Health Brand Promotes Early Action for Fracture Prevention with Recommendations for Improving Bone Health

Press Release Source: Interleukin Genetics, Inc. On Thursday December 17, 2009, 7:30 am EST

WALTHAM, Mass., Dec. 17 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today availability of the Bone Health Genetic Test designed to detect genetic patterns associated with the development of osteoporosis-related outcomes. The test determines an individual's risk for developing vertebral or spinal fractures and low bone mineral density. Knowing one's genetic risk could allow an individual to take action towards building optimal bone health by following personalized guidance outlined in their genetic report, that may include recommendations for certain exercises, changing intake of Calcium and Vitamin D, as well as other lifestyle choices. The Bone Health Genetic Test is available through the Inherent Health brand of genetic tests at www.inherenthealth.com.

The Bone Health Genetic Test was developed following the completion of a 2,500-person clinical study conducted by Interleukin Genetics in collaboration with a university partner. In October at the American Society of Human Genetics 59th Annual Meeting, data from the study was presented by Interleukin Genetics that showed variations in the Interleukin 1 beta (IL1-B), Vitamin D receptor (VDR), and Estrogen receptor 1 (ESR1) genes were strongly associated with risk of spine fracture or low bone mineral density. Association between these variations and vertebral fracture or bone mineral density was determined by logistic regression analysis with adjustment for age, BMI, estrogen use and other covariates.

The Bone Health Genetic Test analyzes gene variations that were identified from the study as showing statistically significantly increased risk for spinal fracture and low bone mineral density and provides risk information beyond that provided by traditional risk factors, such as age and Body Mass Index (BMI), in the assessment of an individual's overall risk for bone health.

"Through knowledge of one's genetic risk for fractures and low bone density, individuals will be able to take appropriate steps to maintain strong bone health prior to any measurable signs. Through proper diet and exercise the opportunity to prevent low bone mineral density and reduce the risk of spinal fracture is significantly improved," said Lewis H. Bender, CEO, Interleukin Genetics. "Not everyone has genetic predisposition for osteoporosis, which can progress painlessly until serious fracture occurs, but for those that do our new Bone Health Genetic Test can be a powerful preventative tool."

Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York
Press Release
Source: Interleukin Genetics, Inc.
On 7:30 am EST, Monday December 7, 2009

WALTHAM, Mass., Dec. 7 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it has received approval by the State of New York's Department of Health for the Company to sell in New York its PST Genetic Test that determines predisposition to severe periodontal disease in individuals. The test has been available in all other States in the U.S. However, through its Clinical Laboratory Evaluation Program (CLEP), New York monitors the accuracy and reliability of results of laboratory tests, including genetic tests, on specimens obtained within the state, setting one of the highest accreditation standards in the country for genetic testing companies.

Interleukin Genetics currently distributes its PST genetic test to dentists through a licensing agreement with OralDNA Labs, a subsidiary of Quest Diagnostics, Inc. This approval will further expand OralDNA Labs' reach to the dentist community with the PST test.

"We are pleased to have met New York's standard for both our laboratory practices and our PST test. This approval by New York further supports our commitment to provide genetic tests that offer strong clinical value," said Lewis H. Bender, CEO, Interleukin Genetics. "PST along with our Heart Health now both meet New York State's unique criteria."

The PST Genetic Test provides a means of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss. PST is the only genetic test available that is capable of identifying which patients are at increased risk for developing severe periodontal disease and can provide dentists and hygienists with important clinical information about their patients. The test is especially useful in patients with early signs of periodontal disease, including recurrent gingivitis and early-to-moderate periodontitis to identify patients more likely to develop severe periodontitis and associated complications.

7:03AM Interleukin Genetics enters partnership agreement with Amway Global to sell Inherent Health Brand of genetic tests (ILI) 0.96 : Co announces that it has entered into an agreement with Amway Global. With this agreement, Amway Global Independent Business Owners will be able to sell Interleukin Genetics' Inherent Health brand of genetic tests, including the new Weight Management Genetic Test.

Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings
Press Release
Source: Interleukin Genetics, Inc.
On 7:00 am EDT, Tuesday October 13, 2009

WALTHAM, Mass., Oct. 13 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it will present new genetic findings in the fields of obesity and osteoporosis at medical meetings later this month. The Company will also exhibit at the American Dietetic Association's (ADA) Food and Nutrition Conference & Expo in Denver, Colo.

Specific presentation details are as follows:

IDF 20th World Diabetes Congress - Montreal, Canada.

Date: October 20, 2009

Time: 1-2 p.m.

Interleukin Genetics will present a poster titled, "Perilipin, IL-1, ADRB and MCR-4 Gene Variants Identify Bariatric Surgery Patients who are Predisposed to Dyslipidemia," at the poster discussion session entitled Complications-dyslipidemia. The poster, #D-0809, will highlight findings that suggest genetic polymorphisms in the perilipin, IL-1, ADRB and MCR-4 genes may predispose to abnormal levels of blood lipids and therefore could have clinical utility in the management of obese patients.

American Society of Human Genetics 59th Annual Meeting - Honolulu, HI

Date: October, 21, 2009

Time: 1-2 p.m.

Interleukin Genetics will present a poster titled, "A Polymorphism in the IL1-B Gene is Associated with Vertebral Fracture Independent of Bone Mineral Density." The poster, #369, will highlight findings that suggest variations in the IL1B, VDR, and ESR1 genes may indicate susceptibility for vertebral fracture or low bone mineral density. These findings should be valuable in guiding medical management of osteoporosis, design of clinical trials of investigational new drugs, as well as guiding preventive treatments for individuals at risk for the disease.

Obesity Society 27th Annual Scientific Meeting - Washington, D.C.

Date: October, 25, 2009

Time: 1-7:30 p.m.

Interleukin Genetics will present a poster titled, "Perilipin, IL-1 and ADRB Gene Variants Identify Bariatric Surgery Patients who are Resistant to Weight Loss under Calorie Restriction in Preoperative Weight Loss Program." The poster, #322-P, highlights findings which suggest that genetic polymorphisms in perilipin, IL-1 and ADRB genes show strong association with resistance to weight loss under caloric restriction. These genetic risk markers could have important clinical utility in the medical management of obese patients and in the design of optimal weight loss programs.

In addition to the scientific presentations, Interleukin Genetics will exhibit at the following conference.

American Dietetic Association FNCE Meeting - Denver, CO

Date: October 17-20, 2009

Booth #1900

Interleukin Genetics will exhibit at the ADA's annual Food and Nutrition Conference & Expo, which will demonstrate the latest nutrition science information and foodservice trends. Highlighted at the Company's Booth will be the new Inherent Health((TM)) Weight Management Genetic Test designed to guide optimal diet and exercise regimens based on genetics.

Interleukin Genetics, Inc. Announces Positive Results from Clinical Study Evaluating Genetic Test's Impact on Weight Loss
Subjects on Diets Appropriate for their Genotype Achieved Statistically significant Average Weight Loss of 6.2% of Body Weight at one year Compared to Individuals not on a Diet Matched to Genotype (2.4%)
Press Release
Source: Interleukin Genetics, Inc.
On Wednesday September 23, 2009, 7:00 am EDT

Companies:Interleukin Genetics Inc.
WALTHAM, Mass., Sept. 23 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today top-line positive results from a retrospective clinical study on weight management using patients who participated in a diet study previously reported in the Journal of the American Medical Association. The new clinical study demonstrated that individuals following diets matched to their genotype, as determined by the Interleukin Genetics Weight Management Genetic Test, showed statistically significant greater weight loss and other benefits at all time points (2 months, 6 months and 12 months) when compared to individuals on diets not matched to their genotype.

Study Design

Overweight/obese premenopausal women participated in a one-year weight loss study comparing four weight loss diets: very low carbohydrate, low carbohydrate/high protein, low fat and very low fat. Beginning in 2008, participants who completed the trial were invited by e-mail and postal mail to provide DNA samples by a simple cheek swab. Of those participants, 145 responded. Genotyping was accomplished in 101 Caucasian participants who were categorized using the Interleukin Genetics Weight Management Genetic Test into three pre-determined composite genotype patterns of individuals who are more likely to respond to calorie reduction diets that are: a) low fat, b) low carbohydrate, or c) balanced in macronutrients. The primary endpoint analysis compared weight loss for women who were on a diet that was consistent with their genotype category to those individuals on diets not suitable for their genetic pattern.

Key Data

Highlights from the studies include:

-- Average weight loss of 6.2% (13.2 lbs) was achieved by individuals who were assigned to the genotype appropriate diets for 12 months versus 2.4% (4.6 lbs) for individuals assigned to inappropriate diets (p=0.013);

-- Average percent change in waist circumference of 6.5% (2.6 inches) was achieved by individuals who were assigned to the genotype appropriate diets for 12 months versus 3.2% (1.2 inches) for individuals assigned to inappropriate diets (p=0.01).

"The outstanding results from this study confirm the positive benefit of applying the proper use of genetics in the field of weight management," stated Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. "Our data indicates that choosing a diet based on genetics provides results comparable to the key industry benchmarks for treatment options in the field of obesity. We intend to submit full data for publication as soon as possible, as well as initiate partnering discussions for distribution of our product with appropriate companies focused on weight management."